Proliferative Pathways of Vascular Smooth Muscle Cells in Response to Intermittent Hypoxia

被引:27
|
作者
Kyotani, Yoji [1 ]
Takasawa, Shin [2 ]
Yoshizumi, Masanori [1 ]
机构
[1] Nara Med Univ, Sch Med, Dept Pharmacol, Kashihara, Nara 6348521, Japan
[2] Nara Med Univ, Sch Med, Dept Biochem, Kashihara, Nara 6348521, Japan
关键词
intermittent hypoxia; vascular smooth muscle cells; epiregulin; interleukin; OBSTRUCTIVE SLEEP-APNEA; NF-KAPPA-B; POSITIVE AIRWAY PRESSURE; SERUM INFLAMMATORY MARKERS; INTIMA-MEDIA THICKNESS; CAROTID-BODY; MAP KINASE; CARDIOVASCULAR EVENTS; INDUCIBLE FACTORS; CANCER;
D O I
10.3390/ijms20112706
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Obstructive sleep apnea (OSA) is characterized by intermittent hypoxia (IH) and is a risk factor for cardiovascular diseases (e.g., atherosclerosis) and chronic inflammatory diseases (CID). The excessive proliferation of vascular smooth muscle cells (VSMCs) plays a pivotal role in the progression of atherosclerosis. Hypoxia-inducible factor-1 and nuclear factor-B are thought to be the main factors involved in responses to IH and in regulating adaptations or inflammation pathways, however, further evidence is needed to demonstrate the underlying mechanisms of this process in VSMCs. Furthermore, few studies of IH have examined smooth muscle cell responses. Our previous studies demonstrated that increased interleukin (IL)-6, epidermal growth factor family ligands, and erbB2 receptor, some of which amplify inflammation and, consequently, induce CID, were induced by IH and were involved in the proliferation of VSMCs. Since IH increased IL-6 and epiregulin expression in VSMCs, the same phenomenon may also occur in other smooth muscle cells, and, consequently, may be related to the incidence or progression of several diseases. In the present review, we describe how IH can induce the excessive proliferation of VSMCs and we develop the suggestion that other CID may be related to the effects of IH on other smooth muscle cells.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Collagen VIII is expressed by vascular smooth muscle cells in response to vascular injury
    Sibinga, NES
    Foster, LC
    Hsieh, CM
    Perrella, MA
    Lee, WS
    Endege, WO
    Sage, EH
    Lee, ME
    Haber, E
    CIRCULATION RESEARCH, 1997, 80 (04) : 532 - 541
  • [42] Hypoxia amplifies the proliferative capacity of distal human pulmonary artery smooth-muscle cells
    Growcott, EJ
    Banner, KH
    Wharton, J
    CHEST, 2005, 128 (06) : 600S - 601S
  • [44] Intermittent high glucose enhances proliferation of vascular smooth muscle cells by upregulating osteopontin
    Sun, Jiazhong
    Xu, Yancheng
    Dai, Zhe
    Sun, Yanlei
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2009, 313 (1-2) : 64 - 69
  • [45] Endothelin-1-induced signaling pathways in vascular smooth muscle cells
    Bouallegue, Ali
    Daou, Grace Bou
    Srivastava, Ashok K.
    CURRENT VASCULAR PHARMACOLOGY, 2007, 5 (01) : 45 - 52
  • [46] CALCIFICATION STIMULATES INFLAMMATORY SIGNALLING PATHWAYS IN HUMAN VASCULAR SMOOTH MUSCLE CELLS
    Proudfoot, D.
    Dautova, Y.
    Kozlova, D.
    Epple, M.
    Bootman, M. D.
    ATHEROSCLEROSIS, 2016, 244 : E9 - E10
  • [47] Pathways of Proliferation New Targets to Inhibit the Growth of Vascular Smooth Muscle Cells
    Marsboom, Glenn
    Archer, Stephen L.
    CIRCULATION RESEARCH, 2008, 103 (10) : 1047 - 1049
  • [48] CCN1 suppresses pulmonary vascular smooth muscle contraction in response to hypoxia
    Lee, Seon-jin
    Zhang, Meng
    Hu, Kebin
    Lin, Ling
    Zhang, Duo
    Jin, Yang
    PULMONARY CIRCULATION, 2015, 5 (04) : 716 - 722
  • [49] Divergent signaling pathways control protein synthesis in vascular smooth muscle cells
    Harding, GEJ
    Del Rizzo, DF
    Zahradka, P
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2001, 33 (06) : A44 - A44
  • [50] INTRACELLULAR SIGNALING PATHWAYS AND BINDING OF ENDOTHELIN IN VASCULAR SMOOTH-MUSCLE CELLS
    CHABRIER, PE
    LONCHAMPT, MO
    ROUBERT, P
    PINELIS, V
    AUGUET, M
    GUILLON, JM
    VIOSSAT, I
    PIROTZKY, E
    HOSFORD, D
    BRAQUET, P
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 183 (03) : 676 - 676